0001935979-26-000072 Sample Contracts
ContractLicensing Agreement • August 26th, 2026 • Biohaven Ltd. • Pharmaceutical preparations
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
PARTIAL MIPA ASSIGNMENT AND ASSUMPTION AGREEMENTPartial Mipa Assignment and Assumption Agreement • August 26th, 2026 • Biohaven Ltd. • Pharmaceutical preparations • New York
This Partial MIPA Assignment and Assumption Agreement (this “Agreement”) dated as of August 26, 2026 (“Signing Date”) and effective on the Closing Date (as defined in the License Agreement), is made between Biohaven Bioscience Ireland Limited (“BBIL”) and SK Biopharmaceuticals Co., Ltd. (“SKBP”). BBIL and SKBP are referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • August 26th, 2026 • Biohaven Ltd. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is entered into as of August 26, 2026 (the “Signing Date”), by and between Biohaven Bioscience Ireland Limited, a limited company organized under the laws of Ireland, at 6th Floor, South Bank House, Barrow Street, Dublin 4, D04 TR29 (“Biohaven”), and SK Biopharmaceuticals Co., Ltd., organized under the laws of the Republic of Korea, having an address at 221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, Republic of Korea (“SKBP”). Biohaven and SKBP may be referred to herein individually as a “Party” or collectively as the “Parties.”